Business
OTC Markets Group Welcomes Newly Verified OTCQB Companies – October 18
OTC Markets Group Welcomes Newly Verified OTCQB Companies – October 18.
About this update from Winston Gold Corp.
[{"type":"text","content":"OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the following companies are verified for trading on the OTCQB® Venture Market:Domain Extremes, Inc. (OTCQB: DNME) – Domain Extremes principal business activities cover Telco operator, Mi1 Station Gallery Cafe, Mobile Reload Top Up, online Bill Payment and online Shopping Mall. All their user's utilize Top Up Credit to reload their mobile phone and pay utility bills online. In addition, point earned can be used to redeem product via the E-mall i.e. MI1 provides an \"Online Shopping (Emall)\" platform for users to purchase a wide range of products such as IT gadgets, mobile phone accessories, bags and more.Protagenic Therapeutics, Inc. (OTCQB: PTIX) – Protagenic Therapeutics has created a proprietary portfolio of novel neuropeptides, in development and preclinical evaluation for the treatment of neuropsychiatric, mood and possibly metabolic disorders.Winston Gold Mining Corp. (CSE: WGC; OTCQB: WGMCF) – Winston Gold Mining Corp., an exploration stage company, engages in acquisition, exploration, development, and operation of mineral properties. It focuses on exploring Holmes and Winston properties located in Broadwater County, Montana. The company was formerly known as 6649930 Manitoba Ltd. and changed its name to Winston Gold Mining Corp. in September 2014. Winston Gold Mining Corp. was incorporated in 2013 and is based in Winnipeg, Canada.Zenosense, Inc. (OTCQB: ZENO) – Zenosense Inc.'s primary focus, through their joint venture ownership with MIDS Medical Ltd., is the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac. MIDS Medical Ltd. applies patent-protected magnetic nanoparticle detection technology and a development team with world-class technical expertise. The MIDS Cardiac device and test strip is being designed to support a variety of rapid high sensitivity cardiac biomarker tests, with a focus on troponin I and T, to identify or discount Acute Myocardial Infarction with accuracy equal or superior to high sensitivity assays performed on laboratory analyzers.U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for these companies on www.otcmarkets.com.About OTC Markets Group Inc.OTC Markets G...